NanoVibronix Cites Positive Results from Independent Testing of UroShield
August 30 2023 - 7:30AM
Business Wire
University of Southampton Study Reports
Positive Outcomes in Lab and Patient Testing
NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that
produces the UroShield®, PainShield® and WoundShield® Surface
Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today
cited positive reported outcomes from a study of UroShield® that
was conducted at the University of Southampton in the United
Kingdom.
Brian Murphy, Chief Executive Officer of NanoVibronix, Inc.,
said, “As the researchers at Southampton point out, incidences of
catheter-associated urinary tract infections (CAUTI) continue to be
a major clinical concern, with serious implications for patients
and considerable impact on healthcare facilities and resources. We
are pleased to learn that through an independent study, researchers
witnessed positive outcomes from the use of UroShield both in the
lab and with patients. Quantitative data from the research
indicated a positive effect of UroShield on catheter-associated
urinary tract infections (CAUTI) and catheter blockage with
approximately one-third of patients in the study citing a reduction
in the frequency of catheter blockages and the need for unscheduled
catheter challenges. Furthermore, qualitative data indicated
favorable opinions from the majority of the participants and
confirmation that the Uroshield was having a positive effect.”
In the study’s hypothesis, the authors wrote,
“Incidence of CAUTI continues to be a major
clinical concern, with serious implications for patients and
considerable impact on healthcare facilities and resources. For
long-term catheter users, there is also the increased risk of
catheter blockage through the formation of crystalline
encrustations due to pH changes in the urine, mediated by the
action of urease-producing bacteria such as Proteus mirabilis. For
both CAUTI and catheter blockages, current management and treatment
methods have limited success with often-repeated use of
antibiotics, which in turn lead to increased risk of resistance
development, or more frequent catheter changes to avoid emergency
call-outs if blocked. There is an urgent need for alternative
strategies and approaches.”
Murphy continued, “Market opportunities for UroShield are
plentiful, and we believe this independent research highlights the
critical need for a medical device that improves outcomes for
long-term catheter users and provides additional evidence to
support our efforts to increase product distribution and market
penetration.”
UroShield generates ultrasonic waves to create an acoustic
shield on the surfaces of a catheter to interfere with the
attachment of bacteria, prevent bacterial biofilm formation, the
development of infections and may eliminate or reduce the need for
antibiotics. It is designed to prevent biofilm formation, decrease
bacteriuria/UTI, reduce catheter pain and discomfort and increase
antibiotic efficacy.
In the study’s concluding message discussing the UroShield
device, the authors wrote,
“... the positive reported outcomes and the
data from these preliminary studies indicate an effect on the
community structure of the microbial populations found in the urine
and forming the biofilm. This indicates potential for developing a
healthy urinary microbiome by use of low frequency ultrasound, thus
avoiding longterm use of antibiotics and the risks associated with
such strategies.”
Understanding the Use of the NanoVibronix® UroShield® in
Preventing Catheter-Associated Infections and Blockage was
published by ScienceDirect and is available at
https://www.sciencedirect.com/science/article/pii/S2772973723005647.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New York, with research and development
in Nesher, Israel, focused on developing medical devices utilizing
its patented low intensity surface acoustic wave (SAW) technology.
The proprietary technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical
applications, including for disruption of biofilms and bacterial
colonization, as well as for pain relief. The devices can be
administered at home without the assistance of medical
professionals. The Company’s primary products include PainShield®
and UroShield®, which are portable devices suitable for
administration at home without assistance of medical professionals.
Additional information about NanoVibronix is available at:
www.nanovibronix.com
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) market acceptance of our
existing and new products or lengthy product delays in key markets;
(ii) negative or unreliable clinical trial results; (iii) inability
to secure regulatory approvals for the sale of our products; (iv)
intense competition in the medical device industry from much
larger, multinational companies; (v) product liability claims; (vi)
product malfunctions; (vii) our limited manufacturing capabilities
and reliance on subcontractor assistance; (viii) insufficient or
inadequate reimbursements by governmental and/or other third party
payers for our products; (ix) our ability to successfully obtain
and maintain intellectual property protection covering our
products; (x) legislative or regulatory reform impacting the
healthcare system in the U.S. or in foreign jurisdictions; (xi) our
reliance on single suppliers for certain product components, (xii)
the need to raise additional capital to meet our future business
requirements and obligations, given the fact that such capital may
not be available, or may be costly, dilutive or difficult to
obtain; (xiii) our conducting business in foreign jurisdictions
exposing us to additional challenges, such as foreign currency
exchange rate fluctuations, logistical and communications
challenges, the burden and cost of compliance with foreign laws,
and political and/or economic instabilities in specific
jurisdictions; and (xiv) market and other conditions. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company’s filings with the Securities and Exchange Commission
(SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are
urged to read these documents free of charge on the SEC’s web site
at: http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events, or otherwise, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230830496027/en/
Investor Contacts:
Brett Maas, Managing Principal, Hayden IR, LLC
brett@haydenir.com (646) 536-7331
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Apr 2024 to May 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From May 2023 to May 2024